Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Core Scientific, Inc. filings document its high-density colocation data center business, digital asset mining activities, capital structure and public-company governance. Recent 8-K reports cover operating and financial results, Regulation FD disclosures, campus expansion updates, material agreements, debt financing and direct financial obligations.
The company’s filings also describe common stock and warrant securities listed on the Nasdaq Global Select Market, subsidiary financing arrangements, senior secured notes, credit agreement amendments, executive and accounting-officer governance matters, and annual proxy disclosures for shareholder voting, board matters and compensation programs.
Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc. (CORZ), reported a transaction on 09/30/2025 showing 8,228 shares of Common Stock disposed at a price of $17.94. The Form indicates these shares were withheld to satisfy tax withholding obligations on vested restricted stock units. After the reported transaction, Mr. DuChene beneficially owns 2,021,428 shares, reported as direct ownership. The Form 4 was signed on 10/02/2025.
Adam Taylor Sullivan, Chief Executive Officer and director of Core Scientific, Inc. (CORZ), reported a transaction on 09/30/2025 in which 23,508 shares of Common Stock were disposed of at a price of $17.94 per share. The filing explains the disposition code F(1) and notes that the sale represented shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. After the reported transaction(s), the filing shows the Reporting Person beneficially owns 4,363,600 shares, and separately discloses an earlier acquisition of 3,555 shares received on 07/17/2025 from an in-kind distribution by XMS XPDI Sponsor Holdings LLC that was exempt from Section 16 under Rule 16a-9.
Two Seas Capital, the largest active shareholder of Core Scientific, Inc., has filed a definitive proxy statement urging investors to vote against the proposed sale of Core Scientific to CoreWeave, Inc. on the GOLD proxy card.
In a letter to shareholders, Two Seas says it supports the strategic logic of combining with CoreWeave but argues the agreed exchange ratio and structure undervalue Core Scientific and expose shareholders to CoreWeave’s highly volatile stock. It points to Core Scientific’s strong position in high-performance computing infrastructure, notes the company has no pressing need to sell, and criticizes what it describes as a one-sided process and transaction. Two Seas also highlights that company executives would receive immediate vesting and tax reimbursements if the deal closes, while shareholders, in its view, lose the chance to benefit from Core Scientific’s long-term AI-driven growth.
CoreWeave and Core Scientific have entered into a merger agreement under which Miami Merger Sub I, Inc. will merge with and into Core Scientific, leaving Core Scientific as a wholly owned subsidiary of CoreWeave.
Each outstanding share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave common stock (cash in lieu of fractional shares). Based on selected trading prices, the implied per-share values were approximately $20.40 (CoreWeave close on July 3, 2025) and $15.64 (CoreWeave close on September 25, 2025). The Core Scientific board unanimously recommends voting FOR the Merger and the advisory compensation proposal.
The record date for voting is September 19, 2025 and proxies must be received by 11:59 p.m. ET on October 29, 2025. Completion is subject to customary conditions including stockholder approval, regulatory clearances (HSR), effectiveness of the Form S-4, no material adverse effect, and Nasdaq listing approval. CoreWeave estimates issuance of approximately 39,685,636 shares at closing and post-closing ownership of roughly 90.6% CoreWeave holders and 9.4% Core Scientific holders. A $270 million termination fee is specified in certain circumstances.